Article info

Download PDFPDF
Adalimumab and etanercept serum (anti)drug levels are not predictive for successful dose reduction or discontinuation in rheumatoid arthritis

Authors

  1. Correspondence to Noortje van Herwaarden, Department of Rheumatology, Sint Maartenskliniek, P.O. Box 9011, Nijmegen 6500 GM, The Netherlands; n.vanherwaarden{at}maartenskliniek.nl
View Full Text

Citation

van Herwaarden N, Bouman CAM, van der Maas A, et al
Adalimumab and etanercept serum (anti)drug levels are not predictive for successful dose reduction or discontinuation in rheumatoid arthritis

Publication history

  • Received April 20, 2015
  • Revised August 2, 2015
  • Accepted August 12, 2015
  • First published September 4, 2015.
Online issue publication 
March 02, 2022

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.